- Home
- RNAZ vs LCFY Comparison
RNAZ vs LCFY Comparison
Compare RNAZ & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- LCFY
- Stock Information
- Founded
- RNAZ 2016
- LCFY 2009
- Country
- RNAZ United States
- LCFY Australia
- Employees
- RNAZ N/A
- LCFY N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- LCFY
- Sector
- RNAZ Health Care
- LCFY
- Exchange
- RNAZ Nasdaq
- LCFY Nasdaq
- Market Cap
- RNAZ 8.7M
- LCFY 9.2M
- IPO Year
- RNAZ 2021
- LCFY 2022
- Fundamental
- Price
- RNAZ $8.60
- LCFY $3.82
- Analyst Decision
- RNAZ Strong Buy
- LCFY
- Analyst Count
- RNAZ 1
- LCFY 0
- Target Price
- RNAZ $280.00
- LCFY N/A
- AVG Volume (30 Days)
- RNAZ 19.3K
- LCFY 20.6K
- Earning Date
- RNAZ 11-14-2025
- LCFY 11-12-2025
- Dividend Yield
- RNAZ N/A
- LCFY N/A
- EPS Growth
- RNAZ N/A
- LCFY N/A
- EPS
- RNAZ N/A
- LCFY N/A
- Revenue
- RNAZ N/A
- LCFY $2,313,843.00
- Revenue This Year
- RNAZ N/A
- LCFY N/A
- Revenue Next Year
- RNAZ N/A
- LCFY N/A
- P/E Ratio
- RNAZ N/A
- LCFY N/A
- Revenue Growth
- RNAZ N/A
- LCFY N/A
- 52 Week Low
- RNAZ $6.15
- LCFY $2.51
- 52 Week High
- RNAZ $468.44
- LCFY $13.98
- Technical
- Relative Strength Index (RSI)
- RNAZ 34.45
- LCFY 24.39
- Support Level
- RNAZ $8.41
- LCFY $3.80
- Resistance Level
- RNAZ $9.85
- LCFY $4.12
- Average True Range (ATR)
- RNAZ 0.68
- LCFY 0.26
- MACD
- RNAZ -0.30
- LCFY -0.02
- Stochastic Oscillator
- RNAZ 11.05
- LCFY 0.93
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.